Abstract-In this study of 10 690 individuals, associations with elevated blood pressure, ischemic heart disease, and ischemic cerebrovascular disease were determined for two noncoding [A(Ϫ20)C, G(Ϫ6)A] and two coding (T174M, M235T) single nucleotide polymorphisms, analyzed alone and in combination (haplotypes). Participants from the general population with (nϭ4950) and without (nϭ4234) elevated blood pressure were compared (study 1), as were participants from the general population without ischemic heart disease and ischemic cerebrovascular disease (nϭ7965) and cases with either ischemic heart disease (nϭ1850, study 2) or ischemic cerebrovascular disease (nϭ848, study 3). Finally, 22-year follow-up of 9184 individuals from the general population examined risk of ischemic heart disease (study 4) and ischemic cerebrovascular disease (study 5). Individuals with Ϫ6AA, 174TT, or 235TT had plasma angiotensinogen levels increased by 80 ng/mL (Pϭ0.01 and 0.05 for women and men) compared with individuals with Ϫ6GG, 174TT, or 235 MM. In women, this difference was associated with an odds ratio of elevated blood pressure of 1.25 (1.03 to 1.51), which increased to 1.63 (1.05 to 2.51) in postmenopausal women receiving hormone replacement therapy. The promoter single nucleotide polymorphisms alone or as haplotypes did not predict the continuous variables of systolic, diastolic, or pulse pressure in cross section or the risk of ischemic heart disease or ischemic cerebrovascular disease in either gender in case-control or prospective studies. Individuals with Ϫ6AA, 174TT, or 235TT in the angiotensinogen gene have increased plasma angiotensinogen levels and moderately increased risk of elevated blood pressure (women only) but unaltered blood pressure examined as a continuous variable and unaltered risk of ischemic heart disease and ischemic cerebrovascular disease. Key Words: blood pressure Ⅲ hypertension, genetic Ⅲ cardiovascular diseases Ⅲ cerebrovascular disorders S ingle nucleotide polymorphisms (SNPs) in the angiotensinogen gene have been associated with elevated angiotensinogen levels, 1 elevated blood pressure, 1 ischemic heart disease (IHD), 2 and ischemic cerebrovascular disease (ICVD). 3 In the Copenhagen City Heart Study, 4 we have previously shown that the M235T SNP (T-allele) was associated with elevated plasma angiotensinogen levels in both genders and a 30% increased risk of elevated blood pressure in women homozygous for 235T. However, the risk of IHD and ICVD was not associated with variation in genotype. 5 SNPs in the transcription factor binding region (Ϫ25 to Ϫ1) of the angiotensinogen gene promoter have been reported to affect gene expression. 6 -8 The Ϫ6A SNP has been associated with increased gene transcription, 8,9 elevated blood pressure, and increased risk of IHD in some 10 -12 but not in all studies, [13] [14] [15] whereas the Ϫ20C SNP has been associated with increased gene transcription, elevated angiotensinogen levels, and elevated blood pressure in one 7 but not in other studies. 1, 10, 15 These conflicting results may be due to small sample size in previous studies, which have included between 301 and 1232 participants.
S
ingle nucleotide polymorphisms (SNPs) in the angiotensinogen gene have been associated with elevated angiotensinogen levels, 1 elevated blood pressure, 1 ischemic heart disease (IHD), 2 and ischemic cerebrovascular disease (ICVD). 3 In the Copenhagen City Heart Study, 4 we have previously shown that the M235T SNP (T-allele) was associated with elevated plasma angiotensinogen levels in both genders and a 30% increased risk of elevated blood pressure in women homozygous for 235T. However, the risk of IHD and ICVD was not associated with variation in genotype. 5 SNPs in the transcription factor binding region (Ϫ25 to Ϫ1) of the angiotensinogen gene promoter have been reported to affect gene expression. 6 -8 The Ϫ6A SNP has been associated with increased gene transcription, 8, 9 elevated blood pressure, and increased risk of IHD in some 10 -12 but not in all studies, [13] [14] [15] whereas the Ϫ20C SNP has been associated with increased gene transcription, elevated angiotensinogen levels, and elevated blood pressure in one 7 but not in other studies. 1, 10, 15 These conflicting results may be due to small sample size in previous studies, which have included between 301 and 1232 participants.
Using Copenhagen City Heart Study control subjects (nϭ7965) and cases with IHD (nϭ1805) and with ICVD (nϭ848), we explored whether these promoter SNPs independently or in combination with the T174M and M235T SNPs as haplotypes predict systolic, diastolic, or pulse pressure in cross section, elevated blood pressure, IHD, or ICVD in 3 case-control studies, or IHD or ICVD in 2 prospective studies. Prospective analyses were also performed for different subtypes of these large entities, for example, myocardial infarction, angina pectoris, ischemic stroke, and transient ischemic attack.
Methods
Three case-control and two prospective studies in the ethnically homogenous Danish population were conducted (Figure I in an online supplement available at http://www.hypertensionaha.org). Study 1 compared individuals from the Copenhagen City Heart Study with (nϭ4950) and without elevated blood pressure (nϭ4234). In studies 2 and 3, individuals in the Copenhagen City Heart Study without IHD and ICVD (controls; nϭ7965) were compared with cases with either IHD (nϭ1805; study 2) or ICVD (nϭ848; study 3). Each of these case groups were a combination of cases from the Copenhagen City Heart Study and patients recruited at Copenhagen University Hospital. Studies 4 and 5 were conducted prospectively within the Copenhagen City Heart Study (nϭ9184). Incident IHD and ICVD cases were recorded in the follow-up period from 1976 through 1997 by reviewing the Danish National Hospital Discharge Register, the Danish National Register of Causes of Death, and medical records from hospitals and general practitioners. 5, 16 Individuals with IHD or ICVD diagnosed before entry into the Copenhagen City Heart Study were excluded in the analysis of IHD risk (nϭ15) and ICVD risk (nϭ31), respectively.
The Copenhagen City Heart Study is a prospective cardiovascular population study recruiting participants randomly from the Danish Central Population Register to obtain a representative sample of the adult Danish general population. 4, 5, 16 The Danish Ethics Committee for Copenhagen and Frederiksberg approved this study (No. 100.2039/91), and all subjects gave informed consent.
During 1991 to 1993, 992 patients from the greater Copenhagen area were referred to Copenhagen University Hospital, Rigshospitalet, for coronary angiography. 5 The study was approved by the Danish Ethics Committees for Copenhagen County (No. KA93125). Similarly, we identified patients with ICVD among patients referred from 1994 to 1999 for outpatient ultrasonography of the carotid artery at Copenhagen University Hospital, Rigshospitalet. 5 The study was approved by the Ethics Committee of Copenhagen and Frederiksberg (No. KF01-375/94, KF01-372/94).
DNA Analyses
The A(Ϫ20)C and G(Ϫ6)A promoter SNPs were diagnosed by PCR 7, 8 : sense primer, 5ЈCTCTCCAGCCTGTGCACAG3Ј; antisense primer, 5ЈGACAAGACCAGAAGGAGCTGA3Ј. The PCR product (158 bp) was digested with either Eco0109I (A[Ϫ20]C), resulting in SNP-specific bands of 130 bp (A-allele) or 67 bp and 63 bp (C-allele) (common bands of 27 and 1 bp), or with MvaI (G[Ϫ6]A), resulting in SNP-specific bands of 133 bp (G-allele) or 78 bp and 55 bp (A-allele) (common band, 25 bp). Individuals with rare haplotypes were sequenced to confirm the diagnoses.
Other Analyses
Plasma angiotensinogen levels were measured in 174TT individuals from the Copenhagen City Heart Study, excluding individuals taking medication or with conditions that potentially affect angiotensinogen levels. Individuals with the genotype 174TT were selected because individuals with the haplotype 235T, 174T had higher risk of elevated blood pressure when compared with the haplotype 235M, 174T. 4 Therefore, among the 6786 individuals homozygous for 174TT in our study population, we randomly selected 300 men and women (40 to 67 years old) distributed equally between the 2 genders and among homozygotes, heterozygotes, and noncarriers of M235T.
Elevated blood pressure was systolic blood pressure Ն140 mm Hg and/or diastolic blood pressure Ն90 mm Hg 17 or treatment with antihypertensive medication. Stratification of elevated blood pressure into mild, moderate, and severe was as previously defined. Blood pressure was measured by trained technicians, using a London School of Hygiene sphygmomanometer on the left arm, after 5 minutes of rest, and with the subject in the sitting position. 4 
Haplotype Estimation and Linkage Disequilibrium
Previous information of linkage disequilibrium and observed haplotypes between T174M and M235T 4 was used together with already published data about linkage disequilibrium between the four examined loci 10 to propose the construction of observed haplotypes (Table  1) . However, to get an objective and thus reliable estimation of haplotype constructions, we also used a linkage utility program (http://linkage.rockefeller.edu), which lists all possible haplotype combinations by frequency, reflecting their estimated probability in our study population. These estimations are based on genotype frequencies of each of the four polymorphisms and their pairwise linkage disequilibrium. 18 In all our statistical analyses, we used the six most frequent haplotypes estimated by the linkage utility program (Table 1) .
Pairwise linkage disequilibrium between the four angiotensinogen SNPs were tested by the linkage utility program, which for each pair of SNPs estimated allele and haplotype frequencies with and without allelic association. The pairwise linkage disequilibrium coefficient D was calculated as DϭP 11 Ϫp 1 q 1 , where P 11 is the observed frequency of the 1/1 haplotype, p 1 is the frequency of the "1" allele at locus 1 in the general population, and q 1 is the population frequency of the "1" allele at locus 2. 19 The "1" allele at each locus is defined as the most common of the alleles at that locus. The extent of disequilibrium was expressed as the DЈϭD/D max . 20 
Statistical Analyses
All statistical analyses were performed stratified by gender and with the use of the SPSS program. A 2-sided probability value Ͻ0.05 was considered significant.
ANOVA and a t test were used to examine continuous variables as a function of genotype or haplotype. Interaction between age, body mass index, alcohol consumption, and genotype or haplotype were examined by means of ANCOVA.
Risk of elevated blood pressure, IHD, and ICVD were examined by logistic regression analysis in age-adjusted, multifactorialadjusted, and matched analyses.
Log-rank tests and Kaplan-Meier curves were used to examine prospective data. Cox regression analysis was used to calculate relative risks (95% CI) adjusted for age at entry into the Copenhagen City Heart Study.
An expanded Methods section can be found in an online supplement available at http://www.hypertensionaha.org.
Results
Characteristics of participants in studies 1 to 5 are shown in Table 2 . 10, 13, 15 Relative allele frequencies of Ϫ20C and Ϫ6A in the general population were 0.16 and 0.40. Linkage disequilibrium was observed in all pairwise combinations of the four SNPs, A(Ϫ20)C, G(Ϫ6)A, T174M, and M235T ( 2 tests, PϽ0.000; Figure II in an online supplement available at http://www.hypertensionaha.org); the degree of linkage disequilibrium between the Ϫ6 and 235 loci was 98%. Table 1 shows observed and estimated haplotype frequencies for 16 possible haplotypes of the A(Ϫ20)C, G(Ϫ6)A, T174M, and M235T SNPs in 9184 individuals from the general population. Statistical analyses below are performed for the A(Ϫ20)C and G(Ϫ6)A SNPs alone and for the 6 most frequent haplotypes.
Plasma angiotensinogen levels were measured in 300 individuals from the general population in either gender. 4 All of these 300 individuals were homozygous for 174T. Individuals on medications known to affect blood pressure or treated with estrogen or other hormones and individuals with suspected liver disease were excluded from the analyses. Plasma angiotensinogen levels were increased by Ϸ80 ng/mL in women with Ϫ6AA versus Ϫ6GG and Ϫ6GA (Pϭ0.03; Pϭ0.04) (Figure 1 ). In men, the association was similar but nonsignificant. However, if individuals were double noncarrier, double heterozygous, or double homozygous for Ϫ6A and 235T, the overall association with angiotensinogen levels became significant in both genders (Pϭ0.01 and Pϭ0.05 in women and men, respectively) ( Figure 1 ). Angiotensinogen levels did not vary as a function of A(Ϫ20)C genotype in either gender (data not shown).
Systolic, diastolic, or pulse pressure did not differ significantly as a function of genotype for the promoter SNPs or as a function of haplotypes in women or men ( Figure 2 ). We did not find evidence for plausible interaction.
On logistic regression analysis adjusted for age, women with Ϫ6AA had an odds ratio for elevated blood pressure of 1.25 (95% CI, 1.03 to 1.51) compared with women with the Ϫ6GG genotype ( Figure 3 ). In accordance with this, women carrying the AATT haplotypes of the Ϫ20, Ϫ6, 174, and 235 loci had an odds ratio for elevated blood pressure of 1.13 (1.02 to 1.26) compared with the AGTM haplotype ( Figure  3 ). Similar odds ratios were found in multifactorial-adjusted analyses (data not shown) and in matched analyses in which each case was matched by gender, age, alcohol consumption, body mass index, and antihypertensive medication with one control (data not shown). In men, neither promoter genotype
TABLE 1. Observed and Estimated Haplotype Frequencies for A(؊20)C, G(؊6)A, T174M, and M235T SNPs in 9184 Individuals From the General Population
*Linkage utility program used for the estimation of haplotypes.
nor haplotypes could predict risk of elevated blood pressure in age-adjusted, multifactorial-adjusted, or matched analyses. When analyzing data stratified by menopausal status and hormone replacement therapy, we found that the observed risk increment in women was confined to postmenopausal women receiving hormone replacement therapy carrying the Ϫ6AA genotype with an age-adjusted odds ratio for elevated blood pressure of 1.63 (1.05 to 2.51) when compared with women with the Ϫ6GG genotype ( Figure 4 ). Correspondingly, postmenopausal women receiving hormone replacement therapy carrying the haplotype AATT had an odds ratio of elevated blood pressure of 1.35 (1.05 to 1.72) compared with the AGTM haplotype ( Figure 4 ). We did not detect other plausible evidence for interaction.
Women homozygous for the Ϫ6AA had an odds ratio for mild elevated blood pressure of 1.33 (1.04 to 1.70) compared with women with the Ϫ6GG genotype ( Figure  5 ). This was not found in men or for moderate or severe elevated blood pressure in either gender. In accordance with this finding, women carrying the haplotype AATT versus the AGTM haplotype had an odds ratio of 1.16 (1.00 to 1.33) for mild elevated blood pressure. Furthermore, when compared with the AGTM haplotype, women carrying the CAMT haplotype had an odds ratio for 
The number of individuals may differ slightly between covariates according to availability of data. BP indicates blood pressure; IHD, ischemic heart disease; ICVD, ischemic cerebrovascular disease; and CCHS, Copenhagen City Heart Study.
moderate elevated blood pressure of 1.36 (1.07 to 1.72) and an odds ratio for severe elevated blood pressure of 2.51 (1.11 to 5.67) if they carried the AGTT haplotype. This was not true for men.
Neither the A(Ϫ20)C and G(Ϫ6)A SNPs nor the haplotypes predicted risk of IHD or ICVD in age-adjusted casecontrol analyses in either gender (Figures 6 and 7) . This was also true for multifactorial-adjusted and for matched analyses, in which each case was matched with two controls by gender, age, total cholesterol, elevated blood pressure, and smoking (data not shown). Although men heterozygous for G(Ϫ6)A had an apparently decreased risk of ICVD (odds ratio, 0.77; 95% CI, 0.62 to 0.95), this turned statistically insignificant in multifactorial-adjusted analysis (0.88; 0.69 to 1.12). Likewise, men heterozygous for A(Ϫ20)C also had a marginally decreased risk of ICVD (0.79; 0.63 to 0.99), which turned insignificant in multifactorial analysis (0.78; 0.60 to 1.02). No plausible significant interactions were found.
The promoter SNPs alone or as haplotypes also could not predict risk of acute myocardial infarction (data not shown).
During 153 412 and 155 722 person-years, 847 and 407 IHD and ICVD events were observed in the Copenhagen City Heart Study, respectively. This results in an incidence rate of 55 IHD cases per 10 000 person-years and 26 ICVD cases per 10 000 person-years. The incidence of IHD and ICVD did not differ between A(Ϫ20)C and G(Ϫ6)A genotypes in either gender. This was also true for the subgroup analyses of myocardial infarction, angina pectoris, ischemic stroke, and transient ischemic attack (data not shown). Similarly, ageadjusted relative risks were nonsignificant for all comparisons between A(Ϫ20)C and G(Ϫ6)A genotypes for the large entities IHD and ICVD as well as for subgroup analyses of myocardial infarction, angina pectoris, ischemic stroke, and transient ischemic attack in both genders. Finally, incidence of IHD, ICVD, and for the different subgroups did not differ among the 6 common haplotypes, and we also did not observe any significant age-adjusted relative risk among haplotypes.
Discussion
In this study, we provide data suggesting that women and men with Ϫ6AA, 174TT, and 235TT (versus Ϫ6GG, 174TT, and 235 MM) in the angiotensinogen gene have increased plasma angiotensinogen levels. This difference was associated with a 63% increase in risk of elevated blood pressure (as a dichotomized variable) in postmenopausal women receiving hormone replacement therapy. In contrast, the Ϫ6A and Ϫ20C promoter SNPs alone or as haplotypes did not predict systolic or diastolic blood pressure (as a continuous variable), pulse pressure, or risk of IHD or ICVD in either gender.
Plasma Angiotensiongen Levels
Both women and men with Ϫ6AA, 174TT, and 235TT (versus Ϫ6GG, 174TT, and 235 MM) had higher angiotensinogen levels. A study in Japanese found no association between the promoter SNPs and plasma angiotensinogen levels. 7 Possible explanations for this divergence could include that we only measured angiotensinogen levels in individuals homozygous for 174T and differences in allele frequencies and linkage disequilibrium caused by different ethnic backgrounds. However, our results are in accordance with previous findings that the Ϫ6A SNP affects basal transcription in vitro and is associated with increased transcription of the angiotensinogen gene. 8 Although we did not observe an association between A(Ϫ20)C and plasma angiotensinogen levels, it is worth emphasizing that this SNP along with another promoter SNP, A(Ϫ217)G, have been suggested to affect basal promoter activity of the angiotensinogen gene. 9,21 Therefore, we cannot exclude that the positive association observed with G(Ϫ6)A might also reflect the effect of other polymorphisms located in the regulatory region of the angiotensinogen gene. 22 
Blood Pressure as a Continuous Variable
None of the A(Ϫ20)C or G(Ϫ6)A genotypes and none of the haplotypes were associated with significant variation in systolic, diastolic, or pulse pressure in either gender. All individuals taking medications known to affect blood pressure were excluded in these analyses. Our finding is in accordance with previous studies showing no association of the G(Ϫ6)A SNP with interindividual variation in blood pressure levels. 13 Similar results were previously found for 235T, which is in nearly complete linkage disequilibrium with Ϫ6A in our study. 4 Although a Japanese study (nϭ274) showed a significant correlation between blood pressure increase and Ϫ6A, 11 we were unable to replicate this in 7120 individuals. A possible explanation for this could be the large difference in allele frequencies of Ϫ6A between the Japanese (84%) and Danish populations (40%).
Blood Pressure as a Dichotomous Variable
Although a previous study of whites found an association between the G(Ϫ6)A SNP and elevated blood pressure, 10 our study is the first to show that this association may be gender-specific, depending on menopausal status and hormone replacement therapy. Failure of previous genderstratified studies [13] [14] [15] to show an association may be due to small sample size and/or lack of stratification by gender. A(Ϫ20)C has previously been shown to modify an estrogenresponsive element located in the regulatory region of the show mean values for all women and men, respectively, in the general population. Individuals taking medications known to affect blood pressure (ie, antihypertensive medications or medication for angina pectoris, heart failure, or cardiac arrhythmias) were excluded from analyses. Probability values are for ANOVA; because all were nonsignificant, no post hoc 2-genotype comparisons were examined.
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angiotensinogen gene. 9 Whether G(Ϫ6)A has a role to play in modifying the estrogen-responsive element is unknown, but others have shown that 235T, which is in complete linkage disequilibrium with Ϫ6A, is associated with greater stimulation of angiotensinogen secretion in plasma after estrogen administration in humans, suggesting an important role of exogenous estrogen administration. 23 Thus, although the interactive relation between G(Ϫ6)A and A(Ϫ20)C on transcriptional regulation of the angiotensinogen gene remains to be examined, our data suggest that G(Ϫ6)A has an important role to play in postmenopausal women treated with hormone replacement therapy. Furthermore, the 235T genotype has been associated with preeclampsia and pregnancy-induced elevated blood pressure 24 in the homozygote state; keeping in mind that Ϫ6A is in near complete (98%) linkage disequilibrium with 235T, this would appear to support our genderspecific finding. The absolute size of the association of genotype with angiotensinogen levels is very similar in women and men: Ϸ80 ng/mL higher in Ϫ6A, 235T homozygotes compared with Ϫ6G, 235M. However, the mean angiotensinogen level in women and men in our study was 861 ng/mL and 811 ng/mL, respectively (Pϭ0.007), suggesting that genotype might have an effect on risk of elevated blood pressure in women, but not in men. That the increased risk for elevated blood pressure overall in women homozygous for Ϫ6AA was seen only in those with mild elevated blood pressure and not in those with moderate and severe elevated blood pressure could be due to the smaller sample size for the analyses of moderate and severe versus mild elevated blood pressure. The significant findings for moderate elevated blood pressure and severe elevated blood pressure in women carrying the CAMT and AGTT haplotypes, respectively, could also be chance findings because of smaller sample sizes for these stratified analyses. In support of this interpretation, no previous reports have examined risk of elevated blood pressure stratified into mild, moderate, and severe elevated blood pressure for the angiotensinogen gene SNPs, and thus these results are not confirmed elsewhere.
Risk of IHD
Both case-control and prospective studies from the Copenhagen City Heart Study suggest that neither promoter SNPs alone nor haplotypes are associated with increased risk of IHD. A recent study including 614 cases and control subjects of both genders found an increased risk of coronary heart disease in individuals homozygous for Ϫ6A SNP on univariate analyses; however, this increase in risk disappeared when adjusted for classic risk factors. 12 
Risk of ICVD
Previous reports suggested local expression of the angiotensinogen gene and its transcription regulators in the brain 25 and development of hypertension when the protein is overexpressed in the brain. 26 Both case-control and prospective studies from the Copenhagen City Heart Study suggest that neither promoter SNPs alone nor haplotypes are associated with increased risk of ICVD. In the case-control studies, men heterozygous for G(Ϫ6)A and A(Ϫ20)C had decreased risk of ICVD when adjusted for age alone; however, these findings disappeared in the multifactorial analyses, were not observed in women, and could not be confirmed in the prospective studies and therefore suggest chance findings.
No previous reports of the promoter SNPs have explored risk of ICVD, but recently we published a report showing no association between the T174M and M235T angiotensinogen SNPs and ICVD. 5 The current study is in agreement with our previous results, when keeping in mind that Ϫ6A is in 98% linkage disequilibrium with 235T in our sample. Figure 5 . Risk of mild, moderate, and severe elevated blood pressure as a function of A(Ϫ20)C and G(Ϫ6)A genotypes (top) and as a function of haplotypes (bottom), using logistic regression, are shown (study 1). Individuals taking medications known to affect blood pressure (ie, antihypertensive medications or medication for angina pectoris, heart failure, or cardiac arrhythmias) were excluded from analyses. 
Mechanism
The end product of the renin-angiotensin system, angiotensin II, may increase blood pressure by stimulating renal sodium reabsorption and vasoconstriction. Our results imply that since one of the promoter SNPs, G(Ϫ6)A, in the homozygous form is associated with a 10% increase (Ϸ80 ng/mL) in plasma angiotensinogen levels, this higher throughput in the renin-angiotensin system raises angiotensin II levels and hence blood pressure. Our data suggest that this may be most pronounced in postmenopausal women receiving hormone replacement therapy. It is therefore tempting to speculate that chronic stimulation of the renin-angiotensin system by estrogen could result in different physiological responses, depending on the G(Ϫ6)A genotype. Although our results suggest that Ϫ6A and 235T in the homozygote state is associated with a moderately increased risk of elevated blood pressure, this association seems too weak to be detected as an increased risk of IHD or ICVD.
Limitations
Blood pressure was only measured once in our study sample. Since intraindividual variation in blood pressure may be considerable, we believe that this represents a limitation of our study. There are several possible explanations as to why there is no association with blood pressure as a continuous variable, whereas there is a moderate association with risk of dichotomized elevated blood pressure in women: (1) The finding for the dichotomous variable is a chance finding. However, the association between genotype and angiotensinogen levels was also most pronounced in women; furthermore, this finding has been confirmed in several other studies, including meta-analyses for the M235T SNP. 27, 28 (2) Misclassification of blood pressure as a dichotomous variable is probable among individuals with blood pressure Ϸ140/ 90 mm Hg, the cutoff point; however, individuals with very high or very low blood pressure are less likely to be misclassified. In contrast to this, when exploring blood pressure as a continuous variable, misclassification will occur on all values. Although categorization of a continuous variable leads to loss of information, this is the only wellunderstood manner in which clinicians treat their patients. (3) The association between the SNP and the continuous variables of systolic and diastolic blood pressure could be so weak that only when combining these two variables into a dichotomous variable, one is able to demonstrate significant association with elevated blood pressure. Also important is the fact that people with clinically recognized hypertension, those who are treated for the condition, are excluded in the analysis of blood pressure as a continuous variable but included in the analysis of elevated blood pressure as a dichotomous variable.
Although genotype determination of T174M and M235T was made in the same PCR reaction enabling unequivocal haplotype determination for these two loci, our analyses of all 4 SNPs (A[Ϫ20]C, G[Ϫ6]A, T174M, and M235T] together naturally cannot be based on unequivocal but only on estimated haplotypes. All individuals can be classified uniquely in terms of his or her 4-loci genotype, but haplotype determination cannot be done uniquely in individuals heterozygous for more than one of the examined loci. These individuals present a difficulty, but omitting them from consideration in an analysis of linkage disequilibrium and haplotype estimation can lead to bias and loss of information for the considered test. Furthermore, it has been shown that exclusion of individuals in whom the phase cannot be uniquely determined a priori results in skewed information about linkage disequilibrium and hence haplotype frequencies. 18 Therefore, a linkage utility program with maximum log likelihood methods that allow these individuals into the analyses was used by us to construct haplotypes used in statistical analyses.
When studying the average haplotype effects on blood pressure and cardiovascular disease, one must keep in mind that statistical analyses were based on each individual divided into two independent haplotypes, each with a set of covariates. This is controversial when adjusting for one or more risk factors in the statistical analyses; however, when confidence intervals were calculated by simple unadjusted 2 estimation, confidence intervals were similar to those shown in Figures 3  through 7 . 
Perspectives
Although the individual risk associated with the two SNPs in homozygous women is Ϸ30%, the attributable risk, that is, the fraction of elevated blood pressure in the population that can be attributed to these SNPs, is Ϸ5% in our female population. This is due to the high prevalence of these alleles in the population and is comparable to the 6% fraction of ischemic heart disease attributable to diabetes mellitus. Future research should be directed toward other genes, because additional genetic factors besides the angiotensinogen gene must be taken into account in modulating risk of elevated blood pressure. This may allow us to define a subset of individuals in whom a special genotype combination is associated with increased risk or especially amenable to a specific kind of antihypertensive treatment. 
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Methods
Participants
The Copenhagen City Heart Study
The Copenhagen City Heart Study is a prospective cardiovascular population study recruiting women and men randomly from the Danish Central Population Register to obtain a representative sample of the adult Danish general population [1] [2] [3] . Individuals invited were stratified 
DNA analyses
The A(-20)C and G(-6)A promoter SNPs were diagnosed by PCR 5;6 : sense primer, 5′CTCTCCAG CCTGTGCACAG3′; antisense primer, 5′GACAAGACCAGAAGGAGCTGA3′.
The PCR product (158 bp) was digested with either Eco0109I (A(-20)C) resulting in SNP specific bands of 130bp (A-allele), or 67bp and 63bp (C-allele) (common bands of 27 and 1bp), or with (common band 25bp). Individuals with rare haplotypes were sequenced to confirm the diagnoses.
Other analyses
Plasma angiotensinogen levels were measured in 174TT individuals from the Copenhagen City Heart Study excluding individuals on medication or with conditions that potentially affect angiotensinogen levels. Individuals with the genotype 174TT were selected because individuals with the haplotype 235T, 174T had higher risk of elevated blood pressure when compared with the haplotype 235M, 174T 3 . Therefore, among the 6786 individuals homozygous for 174TT in our study population, we randomly selected 300 men and women (40 to 67 years old) distributed equally between the 2 genders and among homozygotes, heterozygotes, and noncarriers of M235T.
Elevated blood pressure was systolic blood pressure =140 mmHg and/or diastolic blood pressure =90 mmHg 7 , or treatment with antihypertensive medication. Elevated blood pressure was stratified into mild (systolic blood pressure =140 mmHg and <160 mmHg and/or diastolic blood pressure =90 mmHg and <100 mmHg), moderate (systolic blood pressure =160 mmHg and <180 mmHg and/or diastolic blood pressure =100 mmHg and <110 mmHg), and severe (systolic blood pressure =180 mmHg and/or diastolic blood pressure =110 mmHg). Pulse pressure was systolic minus diastolic blood pressure. Blood pressure was measured by trained technicians using a London School of Hygiene sphygmomanometer on the left arm, after 5 minutes rest, and with the subject in the sitting position 3 .
Haplotype estimation and linkage disequilibrium
Previous information of linkage disequilibrium and observed haplotypes between T174M
and M235T 3 was used together with already published data about linkage disequilibrium between the four examined loci 8 to propose the construction of observed haplotypes (Table 1) . However, in order to get an objective and thus reliable estimation of haplotype constructions we also used a linkage utility program (http://linkage.rockefeller.edu), which lists all possible haplotype combinations by frequency, reflecting their estimated probability in our study population. These estimations are based upon genotype frequencies of each of the four polymorphisms and their pairwise linkage disequilibrium 9 . In all our statistical analyses we have used the six most frequent haplotypes estimated by the linkage utility program (Table 1) .
Pairwise linkage disequilibrium between the four angiotensinogen SNPs were tested by the linkage utility program, which for each pair of SNPs estimated allele and haplotype frequencies with and without allelic association. The pair-wise linkage disequilibrium coefficient D was calculated as follows: D = P 11 -p 1 q 1 where P 11 is the observed frequency of the 1/1 haplotype, p 1 is the frequency of the "1" allele at locus 1 in the general population and q 1 is the population frequency of the "1" allele at locus 2 10 .
The "1" allele at each locus is defined as the most common of the alleles at that locus. The extent of disequilibrium was expressed as the D' = D/D max 11 .
Statistical analyses
All statistical analyses were performed stratified by gender and using the SPSS program.
A two-sided p-value <0.05 was considered significant.
Log-rank tests and Kaplan-Meier curves examined prospective data. Cox regression analysis was used to calculate relative risks (95% CI) adjusted for age at entry into The Copenhagen City Heart Study. I.
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